Physician profile
Mohammad Hashmi
NPI 1528467917
$2,349.49
in general payments reported to CMS, 2019-2025
20 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $122 · 2023: $266 · 2024: $1,734 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,337 · Travel and Lodging: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.54 |
| Travel and Lodging | $890.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $852.41 | 2024 | Corevalve Evolut R |
| Abiomed | $529.36 | 2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $160.62 | 2023-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $153.58 | 2022-2024 | |
| Biotronik INC. | $148.20 | 2023-2024 | Acticor 7 Vr-T Dx, Biomonitor |
| Calliditas Therapeutics US INC. | $82.51 | 2022 | |
| W. L. Gore & Associates, INC. | $68.04 | 2023 | Gore Cardioform Septal Occluder |
| Merck Sharp & Dohme LLC | $50.04 | 2024-2025 | Prevymis |
| Novartis Pharmaceuticals Corporation | $46.88 | 2025 | |
| Veloxis Pharmaceuticals, INC. | $45.83 | 2025 | Envarsus |
| Vifor Pharma, INC. | $31.54 | 2024-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $31.16 | 2022-2024 | Velphoro |
| Janssen Pharmaceuticals, INC | $26.42 | 2023 | Xarelto |
| Ardelyx, INC. | $22.24 | 2024 | Ibsrela |
| Amgen INC. | $19.39 | 2025 | Tavneos |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $18.30 | 2024 | Quikclot |
| Apellis Pharmaceuticals, INC. | $17.20 | 2025 | Empaveli |
| Glaxosmithkline, LLC. | $15.97 | 2023 | Benlysta |
| Mallinckrodt Hospital Products INC. | $15.45 | 2025 | Acthar |
| Philips North America LLC | $14.35 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Hashmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.